Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Adverse drug reactions

Medication-related harm in older adults costs the NHS £400m each year, study finds

In the first UK study to investigate medication harm in older adults following hospital discharge, the authors concluded that there was “considerable scope for improving patient safety”.

Woman's hand holding pills

 

Source: The Pharmaceutical Journal

Researchers recruited over 1,000 older adults, with a median age of 82 years, in the first UK study to investigate medication harm in older adults following hospital discharge.

Medication-related harm (MRH) affects one in three older adults and incurs an annual cost of around £400m to the NHS, most of which is attributable to hospital readmissions, a study has found[1].

In the first UK study to investigate medication harm in older adults following hospital discharge, researchers recruited over 1,000 older adults, with a median age of 82 years, discharged from five teaching hospitals in the south of England.

The participants were followed up for eight weeks by senior research pharmacists using three sources of data: hospital readmission reviews, participant and/or carer telephone interviews, and primary care records, in order to identify MRH and associated use of healthcare resources.

MRH was defined as an adverse drug reaction or harm arising from a failure to receive medication due to non-adherence.

Of the 1,116 participants included in the final cohort, 413 (37%) experienced MRH, representing 556 events per 1,000 participants over an eight-week timeframe. Three hundred and thirty‐six (81%) cases were serious, and 214 (52%) were potentially preventable.

Over 70% of these events were attributable to medicines prescribed at hospital discharge, with the remainder prescribed in the community.

Adverse drug reactions (ADRs) were solely responsible for MRH in 301 of the 413 cases (73%), non-adherence in 45 cases (11%) and a medication error in 14 cases (3%). In five cases patients experienced harm from both an ADR and a medication error, and in 48 cases harm was due to both an ADR and non-adherence.

Four participants (1%) experienced a fatal event associated with MRH: one following a fall, one from a major gastrointestinal bleed, one from a stroke, and one from a lower respiratory tract infection.

The main body systems affected by MRH were gastrointestinal (25%) and neurological (18%), and the most common events were diarrhoea, constipation, falls and bleeding.

The medicines most associated with harm were opiates, antibiotics and benzodiazepines.

The researchers classified the MRH as “definitely” preventable in 44 cases and “possibly” preventable in 170 of cases.

In terms of costs, the researchers calculated that the cumulative NHS cost over the 8-week period after hospital discharge was £225,747, an average cost per participant with MRH of £546.60. Hospital readmissions accounted for 93% of total costs.

They estimated that the annual cost to the NHS of MRH post-discharge in older adults was £395.5m and the cost of preventable MRH was between £51.6m and £243.4m per year.

The authors concluded that, given the high proportion of preventable MRH in the study, there was “considerable scope for improving patient safety”.

“As the use of medicines in the ageing population is rapidly increasing, it’s vital that we improve awareness among clinicians of the harm that medicines commonly cause,” said Chakravarthi Rajkumar, senior investigator on the study and chair of geriatrics and stroke medicine at Brighton and Sussex Medical School. 

“The risk-to-benefit analysis is particularly complex in the older population. Any decision to prescribe medicines should be made in close collaboration with patients and carers, with a tentative stop date and with monitoring of correct usage and adverse reactions,” he added.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20204894

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Statistics

    Pharmaceutical Statistics

    This book on basic statistics has been specifically written for pharmacy students.

    £33.00Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Woman's hand holding pills

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.